Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.44 USD | +2.05% |
|
+0.06% | +71.15% |
02/06 | Transcript : Cullinan Therapeutics, Inc. - Special Call | |
01/06 | Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.15% | 1.01B | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing